myristic acid has been researched along with Granulocytic Leukemia, Chronic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, C; Wu, D; Wu, X; Xie, Y; Xu, L; Yang, B | 1 |
| Botta, M; Radi, M; Schenone, S | 1 |
| Chen, S; Engen, JR; Iacob, RE; Panjarian, S; Smithgall, TE; Wales, TE | 1 |
| Chen, S; Engen, JR; Iacob, RE; Panjarian, S; Smithgall, TE | 1 |
2 review(s) available for myristic acid and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket binders.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myristic Acid; Protein Kinase Inhibitors | 2013 |
Structure and dynamic regulation of Abl kinases.
Topics: Benzamides; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Chemical; Molecular Conformation; Mutation; Myristic Acid; Piperazines; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Mas; Pyrimidines; src Homology Domains | 2013 |
2 other study(ies) available for myristic acid and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients.
Topics: Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Gas Chromatography-Mass Spectrometry; Glycerol; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metabolome; Metabolomics; Myristic Acid; Protein Kinase Inhibitors; ROC Curve | 2018 |
Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors.
Topics: Binding Sites; Cell Line, Tumor; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myristic Acid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; src Homology Domains | 2013 |